Now in its 20th year, The Max Foundation is undergoing exciting strategic changes aimed at strengthening organizational efforts to improve global access to cancer treatment, care and support. To that end, we announce the launch of MaxAid, a subsidiary organization set up by The Max Foundation to further its mission. MaxAid is a Washington nonprofit corporation with its own IRS determination letter of 501(c)(3) public charity status.
From its launch, MaxAid will host our collaboration with Novartis, a leading global healthcare company, around humanitarian access to their medicines Glivec® and Tasigna® in a joint initiative. In the future similar contributions from other partnering companies may also be received by MaxAid.
“The advent of MaxAid is exciting for The Max Foundation because it enables us to take our operational work to the next level,” says Paula Boultbee, Chair of the Board for The Max Foundation. She continues, “By launching MaxAid, we accomplish yet another strategic milestone for The Max Foundation in our role as a bridge to access for people facing cancer currently without treatment in lower resource settings around the world.”
This positive step of launching MaxAid in 2017 promises to keep us well positioned to decrease avoidable cancer deaths in the least developed countries and help people around the world to face cancer with dignity and hope.